帕拉米韦治疗流行性感冒的疗效及安全性分析

Safety evaluation of peramivir in the treatment of influenza

目的帕拉米韦是新型的抗病毒药物,本研究拟评价帕拉米韦治疗流行性感冒的临床安全性。方法以北京大学第三医院感染疾病科发热门诊就诊的流行性感冒患者89例为研究对象,所有患者均给予帕拉米韦氯化钠注射液3mg?mL-1治疗,单次静脉滴注,评价其发热、呼吸道和全身症状的缓解情况和药物的安全性。结果患者平均年龄(28.31±8.30)岁。诊断为甲型流感84例,乙型流感5例。治疗后7d随访,发热均缓解,缓解时间(24.92±14.44)h。主要不良事件包括消化道症状5例(5.62%),神经系统症状3例(3.37%)。心电图由治疗前的窦性心律变为治疗后的窦性心动过缓9例(10.11%),窦性心律不齐6例(6.74%),2例治疗后QTc间期延长。治疗前正常,治疗后2例丙氨酸氨基转移酶异常,15例(16.85%)甘油三酯升高,6例(6.74%)网织红细胞异常。无严重不良事件。结论帕拉米韦治疗流行性感冒的安全性相对较高。

Objective:To evaluate the clinical safety of peramivir,a new antiviral drug,in the treatment of influenza.Methods:Eightynine influenza patients treated in the fever clinic of the infectious diseases department of the Peking University Third Hospital were selected as the subjects.All the patients were given a single dose intravenous infusion of peramivir sodium chloride injection 3 mg·mL-1.The remission of fever,respiratory and systemic symptoms,and the safety of the drugwere evaluated.Results:Among the 89 patients,with an average age of(28.31 ±8.30)years.The diagnosis included 84 cases of influenza A and 5 cases of influenza B.Fever all responsed,and the alleviate time was(24 92±14.44) h.The adverse events were mainly including gastrointestinal symptoms(5,5.62%) and neurological symptoms(3,3.37%).Sinus bradycardia(9,10.11%) and sinus arrhythmia(6,6.74%) was found in the electrocardiogram after treatment which was sinus rhythm before treatment QTc interphase was prolonged in 2 cases after treatment.Abnormal ALT in 2 cases,elevated triglyceride in 15 cases(16.85%) and abnormal reticulocyte in 6 cases(6.74%) which were normal before treatment.No serious adverse events happened.Conclusion:Combined with the results of this study,peramivir is relatively safe in treatment of influenza.